Inflammatory syndromes in general, and primary vasculitis specifically, present a high risk of cardiovascular involvement. Takayasu arteritis (TAK), for example, presents cardiovascular complications in up to 60% of cases. It is a systemic inflammatory disease that primarily affects large vessels, such as the aorta and its main branches. From a pathophysiological point of view, there are several causes that can lead to an exacerbated increase in cardiovascular risk in this population, including accelerated atherosclerosis, pro-inflammatory action of platelets and significant endothelial dysfunction. In this context, the present case-control study intends to include 100 individuals (50 with TAK - case group, and 50 healthy volunteers - control group), matched by age and sex in a 1:1 ratio. The main objective of the study is to compare platelet aggregability in patients with TAK against healthy volunteers using the AggRAM® test. Among its secondary objectives is the analysis of platelet aggregability by other methods (Plateletworks, Chronolog, and PPAnalysis). The study aims to significantly contribute to a better understanding of the potential influence of TAK on platelet aggregation and the response to antiplatelet agents, thereby contributing to a better understanding of the disease, with evident prognostic and therapeutic implications.
Study Type
OBSERVATIONAL
Enrollment
100
Clopidogrel 75 mg once a day for 14 days.
Heart Institute (InCor) / University of São Paulo, São Paulo
São Paulo, São Paulo, Brazil
Platelet Aggregation analyzed by optical aggregometry-ADP (AggRAM™- Helena Laboratories)
Compare platelet aggregation analyzed by optical aggregometry-ADP (AggRAM™- Helena Laboratórios) between both groups
Time frame: 14 days
Platelet aggregability by AggRAM™ arachidonic acid at baseline;
Avaliation of Platelet aggregability by AggRAM™ arachidonic acid at baseline
Time frame: Baseline
Platelet aggregability by AggRAM™ ADP after 14 days of use of Clopidogrel 75 mg/day;
Evaluation of Platelet aggregability by AggRAM™ ADP after 14 days of use of Clopidogrel 75 mg/day;
Time frame: 14 days
Platelet aggregability by Plateletworks-ADP at baseline and after 14 days of use of Clopidogrel 75 mg/day
Evaluation of Platelet aggregability by Plateletworks-ADP at baseline and after 14 days of use of Clopidogrel 75 mg/day;
Time frame: 14 days
Serum levels of ultrasensitive C-reactive protein (hs-CRP);
Avaliation of Serum levels of ultrasensitive C-reactive protein (hs-CRP)
Time frame: Baseline
Serum levels of immature platelets;
Evaluation of Serum levels of immature platelets
Time frame: Baseline
Platelet count
Evaluation of Platelet count;
Time frame: Baseline
Serum levels of P-Selectin
Evaluation of Serum levels of P-Selectin
Time frame: Baseline
Serum levels of interleukin 6
Evaluation of Serum levels of interleukin 6;
Time frame: Baseline
Serum levels of Interleukin 1
Evaluation of interleukin 1
Time frame: Baseline
Serum levels of cholesterol ester transfer proteins;
Evaluation of Serum levels of cholesterol ester transfer proteins;
Time frame: Baseline
Serum levels of Lipoprotein(a) (LPa)
Evaluation of Serum levels of Lipoprotein(a) (LPa)
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.